



# Genomic landscape of biliary tract cancer and corresponding targeted treatment strategies

Daisaku Yamada<sup>1</sup> · Shogo Kobayashi<sup>1</sup> · Yuichiro Doki<sup>1</sup> · Hidetoshi Eguchi<sup>1</sup>

Received: 17 February 2025 / Accepted: 27 March 2025 / Published online: 25 April 2025  
© The Author(s) 2025

## Abstract

Biliary tract cancers (BTCs) are classified on the basis of their anatomical origin, and the feasibility of surgical resection depends on the tumor location and extent of progression. However, for unresectable BTCs, systemic therapy has been uniformly applied. Gemcitabine and cisplatin (GC) therapy and GC-based therapies were established as the first-line standard BTC treatment. However, no highly effective second-line therapy has been established, and the prognosis remains poor, highlighting the need for further therapeutic advancements. Meanwhile, the era of precision medicine has expanded the use of genetic testing, leading to the identification of actionable molecular targets in BTC. Several targeted therapies, including FGFR inhibitors and IDH1 inhibitors, have been developed, offering new second-line treatment options and the potential for first-line use in appropriate cases. Notably, the frequency of these genetic alterations varies depending on the tumor location, demonstrating the molecular heterogeneity of BTC. Therefore, it has been recognized that a tailored treatment approach for each BTC patient may be more effective than uniform systemic therapy. Consequently, although routine genetic testing before initiating systemic treatment is currently limited by the medical environment (e.g., cost, accessibility, regional differences), it is recommended in ESMO guideline and might be increasingly advocated. However, BTC harbors a wide range of genetic alterations, and numerous targeted therapies are being developed accordingly. This review provides an overview of the reported genetic alterations in BTC, the frequencies of these alterations, and the corresponding targeted therapies, emphasizing the evolving role of precision medicine in BTC treatment.

**Keywords** Biliary tract cancer · Cancer genome testing · Target therapy

## Introduction

Biliary tract cancer (BTC) arises from cholangiocytes located along the biliary tree, from the intrahepatic ducts to the ampulla of Vater. Classifications of BTC are highly diverse. On the basis of its anatomical origin, BTC can be categorized as intrahepatic cholangiocarcinoma (iCCA) or extrahepatic cholangiocarcinoma (eCCA). eCCA can be further subclassified into perihilar cholangiocarcinoma (pCCA), distal cholangiocarcinoma (dCCA), or gallbladder cancer (GBC). Additionally, ampulla of Vater carcinoma (AVC) is considered distinct subclass and may be classified as a biliary, pancreatic, or duodenal cancer on the basis of its

cellular origin. While AVC is included as a subset of BTC according to some classifications [1], it is excluded in other classifications [2]. Although BTC is a rare malignancy, its incidence is increasing worldwide [3].

Historically, the classification of BTC has been aligned with therapeutic objectives. Anatomical classification is useful for assessing the extent of tumor progression and determining the appropriate surgical approach for treatment. For example, BTCs requiring hepatic resection, extrahepatic bile duct resection, or pancreaticoduodenectomy have been grouped accordingly. However, for unresectable BTCs, systemic chemotherapy has been applied universally, treating BTCs as a single entity originating from cholangiocytes. The landmark ABC-02 trial in 2010 established gemcitabine and cisplatin (GC) therapy as the standard BTC treatment [4]. GC therapy is effective for advanced BTC, and several novel therapies based on GC therapy have been tested [5, 6], with some demonstrating superior efficacy [7–9]. However, no second-line treatment has been established with sufficient

✉ Shogo Kobayashi  
s-kobayashi@umin.ac.jp

<sup>1</sup> Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2E2, Yamadaoka, Suita City, Osaka 565-0871, Japan

efficacy, and the median overall survival for advanced BTC remains less than one year in most reports [10].

Recent advancements in genomic analysis have shed light on the genetic alterations underlying BTC [11–24]. In particular, iCCA has emerged as a focus of genomic research because of the feasibility of obtaining adequate tumor samples for analysis [25]. Studies have revealed actionable mutations such as FGFR and IDH1/2 alterations, leading to the development of targeted therapies that have progressed through phase II/III trials [26–29] and are now widely used in clinical practice (Table 1) [26–35]. These successes have spurred further genomic investigations for other BTC subtypes, resulting in the identification of additional actionable mutations and the ongoing development of novel targeted therapies (Tables 1, 2).

Interestingly, distinct genomic profiles among BTC anatomical classification subtypes have been revealed (Table 1). This finding might indicate that tumor location and the associated microenvironment play significant roles in carcinogenesis, even among cancers originating from cholangiocytes. Environmental factors also appear to influence BTC incidence, as evidenced by geographical and ethnic variations. For example, the incidence of BTC tends to be higher among Asians, particularly in Asian countries (incidence rate in Asia: 3–10/100,000 population;

incidence rate in Europe or America: 1–3/100,000 population) [10, 36, 37].

Given the heterogeneity of BTC, the limitations of a one-size-fits-all therapeutic regimen have become apparent. Precision medicine, involving the selection of appropriate therapies tailored to the specific genetic and molecular characteristics of each patient's BTC, is increasingly recognized as essential [20, 38–43]. Actionable mutations are identified in one-third to one-half of BTC cases [44, 45]. In their BTC management guidelines, the European Society for Medical Oncology (ESMO) proposes a treatment strategy for advanced BTC in which genomic testing is performed upfront and targeted therapies are prioritized when actionable mutations are present [41]. In the absence of such mutations, systemic chemotherapy remains the standard of care [46]. The NCCN guideline also recommends performing genomic testing for BTC patients being considered for systemic chemotherapy [2].

Thus, genomic testing and targeted therapy are rapidly becoming central to the management of BTC. The aim of this review is to summarize the current status of genomic testing, the targeted therapies available in clinical practice, and promising future developments.

**Table 1** Frequencies of gene mutations and target drugs

Gene mutation	iCCA		eCCA		Valid target drugs (FDA-approved)	Phase	Outcomes
	Rank	Frequency	Rank	Frequency			
<i>KRAS</i>	#1	7–54%	#2	37–57%	None		
<i>TP53</i>	#2	18–27%	#1	18–68%	None		
<i>ARID1A</i>	#3	18–23%	#5	14%	None		
<i>IDH1/2</i>	#4	7–30%	#10	0–5%	Ivosidenib	III	Prolonged PFS, 2.7 vs. 1.4 months
<i>CDKN2A/B</i>	#5	9–27%	#3	9–28%	None		
<i>EGFR</i>	#6	8–27%	#9	1%	None (Failure)		
<i>FGFR2</i>	#7	5–16%	#11	0–4%	Pemigatinib Futibatinib	II II	ORR 35.5%, PFS 6.9 months ORR 41.7%, PFS 9 months
<i>PI3K</i>	#8	7%	#7	5%	None		
<i>ERBB2</i>	#9	3–8%	#4	1–27%	Zanidatamab	IIb	ORR 41.3%, PFS 5.5 months
<i>BRAF</i> <sup>V600E</sup>	#10	1–5%	#12	< 1%	Dabrafenib + trametinib	II	ORR 53% PFS 9.0 months
<i>BRCA1/2</i>	#11	0–3%	#8	2–3%	Standard chemotherapy (GC regimen)		
<i>RET</i>	#12	0–6%	-	-	None		
<i>NTRK</i>	#13	< 1%	#13	< 1%	Entrectinib* Larotrectinib*	I/II I/II	ORR 100%***, PFS 9.3*** months ORR 50%†, PFS 7.3†months
<i>SMAD4</i>	–	–	#6	11–25%	None		

iCCA intrahepatic cholangiocarcinoma, eCCA extrahepatic cholangiocarcinoma, FDA U.S. Food & Drug Administration, PFS progression-free survival, ORR objective response rate, GC gemcitabine and cisplatin

\*Solid tumor

\*\*Only one BTC case was included

†Two cholangiocarcinoma cases were included

**Table 2** Possible targeted drugs for gene mutations

Target	Objectives	Clinical trial identifier	Phase	Possible targeted drugs	Outcomes
<i>KRAS</i>	Solid tumors	NCT05162443	II	Adagrasib (G12C)	DCR: 100% ( $n = 8$ )
		NCT04185883	Ib	Sotorasib (G12C)	Ongoing
		NCT05737706	I/II	MRTX1133 (G12D)	Ongoing
<i>TP53</i>	Solid tumors	NCT04383938	I/II	Eprenetapopt + pembrolizumab	BTC patients were not included
<i>ARID1A</i>	Solid tumors	NCT05023655	II	Tazemetostat	Ongoing
<i>IDH1/2</i>	Solid tumors	NCT03684811	I/II	Olutasidenib	ORR: 12.5% ( $n = 8$ )
		NCT02273739	I/II	Enasidenib	BTC patients were not included
<i>CDKN2A/B</i>	Solid tumors	NCT02693535	II	Abemaciclib	Ongoing
		NCT02693535/NCT03297606	II/	Palbociclib	Ongoing
		NCT04116541/NCT02187783	II	Ribociclib	Ongoing
			II/		Ongoing/
<i>EGFR</i>	BTC	NCT04838964	II	MRG003	only one GBC patient included
<i>FGFR2</i>	CCA	NCT02150967	II	Infgratinib	Ongoing
		NCT03773302	III	Derazantinib	ORR: 23.1% ( $n = 108$ )
		NCT01752920	I/II		Early termination
		NCT04087876	II		ORR: 8.6% ( $n = 58$ )
<i>PI3K</i>	Solid tumors	NCT06739395	II	Alpelisib	Ongoing
<i>ERBB2</i>	BTC	NCT06467357	III	Trastuzumab-deruxtecan	Ongoing
	Solid tumors	NCT05150691	I/IIa	Trastuzumab + pertuzumab	ORR: 23.1% ( $n = 39$ )
	CCA	NCT02999672	II	Trastuzumab-emtansine	ORR: 14.3% ( $n = 7^*$ )
	Solid tumors	NCT06519110	II	Neratinib	Ongoing
	Solid tumors	NCT04579380	II	Trastuzumab-tucatinib	ORR: 46.7% ( $n = 30$ )
<i>BRAF<sup>V600E</sup></i>	Solid tumors	NCT02693535	II	Vemurafenib + cobimetinib	Only 2 BTC patients included
	Malignancy	NCT05768178	II/III		Ongoing
<i>BRCA1/2</i>	BTC	NCT05222971	II	Olaparib	Ongoing
<i>RET</i>	Solid tumors	NCT03157128	I/II	Selpercainib	Only one BTC patient included
	Solid tumors	NCT03037385	I/II	Pralsetinib	ORR: 66% ( $n = 3$ )
<i>SMAD4</i>	Solid tumors	NCT04116541	II	Regorafenib	Ongoing

DCR disease control rate, BTC biliary tract cancer, GBC gallbladder cancer, ORR objective response rate

\*Included cases of pancreatic cancer

## Landscape of genomic alterations across BTC subtypes

To consolidate existing reports [12, 14, 16, 22], BTC is categorized into iCCA and eCCA in this review, and a summary of genomic mutation findings is provided. As shown in Table 1, some mutations are shared between subtypes, but the frequencies of these mutations differ significantly between iCCA and eCCA.

### iCCA

Genomic mutations in iCCA have been extensively reported, with the number of publications increasing yearly. The variety in mutation types and frequencies reported may reflect differences in epidemiology, treatment environments, and sample collection and preservation conditions across studies. However, there are also significant commonalities. Frequently reported mutations include those in *KRAS*, *TP53*, *ARID1A*, *IDH1/2*, *CDKN2A/B*, *EGFR* and *FGFR*. Less frequent

mutations, such as those in *PI3K*, *ERBB2* and *BRAF*, have also been reported. Furthermore, although rare, actionable mutations such as *NTRK* fusions and *RET* fusions are relatively well documented (Table 1).

### eCCA

There are fewer reports of genomic mutations in eCCA than in iCCA, but the number of such reports is increasing. Common mutations in eCCA include those in *KRAS*, *TP53* and *CDKN2A/B*, whereas *ERBB2* mutations, which are frequently reported in eCCA, occur at lower frequencies in iCCA. Both *IDH1/2* mutations and *FGFR* mutations are rare in eCCA (Table 1).

## Genetic mutations frequently found in BTC

### IDH1/2 (isocitrate dehydrogenase 1/2) mutations

IDH1 mutations are observed in 7–30% of BTCs, predominantly in iCCA (Table 1) [27, 44, 47–54]. IDH1/2 proteins normally participate in energy metabolism, producing  $\alpha$ -ketoglutarate ( $\alpha$ KG) from isocitrate with NADP<sup>+</sup> as a coenzyme. However, mutant IDH1/2 proteins cannot produce  $\alpha$ KG and instead produce D-2-hydroxyglutarate (D2HG) in an  $\alpha$ KG-dependent manner, using NADPH as a coenzyme. This change in function inhibits  $\alpha$ KG-dependent dioxygenases, disrupting the activity of related enzymes and affecting the hypoxia response and epigenetic regulation, thereby contributing to tumor progression. Recently, IDH1 inhibitors (e.g., ivosidenib) have been developed, and their efficacy in BTC was demonstrated in a phase III trial (ClarIDHy trial, Table 1) [26, 27]. Owing to their mechanism of action, IDH1 inhibitors can have broad impacts on tumors and differ fundamentally from cytotoxic anticancer agents, making further research into their use as first-line treatments or in combination with existing therapies highly promising [52, 54]. Another IDH1 inhibitor, olutasidenib, has been approved for the treatment of hematologic malignancies and has also shown efficacy in BTC (Table 2) [55]. For IDH2 mutations, enasidenib has been developed and tested in clinical trials for the treatment of solid tumors (Table 2). However, patients with BTC were not included in this trial, leaving room for further investigation. In the future, additional research into IDH-targeted therapies for BTC is highly anticipated.

### FGFR (fibroblast growth factor receptor) mutations

FGFR mutations are observed in 5–16% of BTCs, primarily in iCCA (Table 1) [51–54, 56–59]. FGFR2 fusion proteins produced from these genes activate tyrosine kinases in a ligand-independent manner, leading to the activation of the FGFR pathway. FGFR pathway activation, in turn, activates downstream pathways, including the MAPK, PI3K-AKT, and STAT pathways, promoting antiapoptotic effects and cell proliferation. FGFR has five subunits (FGFR1–5), and several FGFR inhibitors (pemigatinib, an FGFR1–3 inhibitor; infigratinib, an FGFR1–5 inhibitor; futibatinib, an FGFR1–4 inhibitor; and derazantinib, an FGFR1–3 inhibitor) have been developed, with therapeutic efficacy demonstrated in phase II trials (Tables 1, 2) [28, 29, 60, 61]. Clinical trials have demonstrated the efficacy of these FGFR inhibitors as monotherapies in patients with FGFR mutations following standard treatment. Among these drugs, pemigatinib and futibatinib are approved for use in BTC by the FDA (U.S. Food & Drug Administration, <https://www.fda.gov/>).

Currently, international phase III trials are ongoing to compare these drugs with GC treatment as first-line therapy (NCT03656536 [62], NCT03773302 [63], and NCT04093362). Further studies, such as studies in which synergistic effects with existing anticancer agents are evaluated, are highly anticipated.

### ERBB2 (v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2) mutations

ERBB2 aberrations are identified in 3–8% of iCCA cases and 1–27% of eCCA cases (Table 1) [44, 52, 53, 64–67]. Cancer cells with ERBB2 aberrations overexpress HER2 (human epidermal growth factor receptor 2) receptors, increasing ligand sensitivity and activating downstream pathways (e.g., the MAPK and PI3K-AKT pathways). Molecular targeted therapies for BTC, such as trastuzumab, deruxtecan, pertuzumab, tucatinib and emtansine, which were initially developed for HER2-positive breast cancer, have been tested in phase II trials with favorable outcomes (Table 2) [68–71]. Among these, zanidatamab has been approved by the FDA for the treatment of HER2-positive BTC, demonstrating an objective response rate (ORR) of 41.3% and a progression-free survival (PFS) of 5.5 months in the HERIZON-BTC-01 trial [30]. Further clinical trials are ongoing (Table 2), and additional data are anticipated.

## Common genetic mutations in cancer

### KRAS (Kirsten rat sarcoma viral oncogene homolog) mutations

Currently, there is no approved standard therapy targeting KRAS mutations in BTC. However, since KRAS mutations are relatively common in BTC (7–57%, Table 1) [44, 49, 51, 72–74], targeted therapy development is ongoing. Among KRAS mutations in BTC, the G12C mutation is rare (~1–2%), but KRAS G12C inhibitors, such as adagrasib and sotorasib, have already been approved by the FDA for the treatment of non-small cell lung cancer (NSCLC) and are now being investigated in clinical trials for the treatment of BTC (Table 2). Reports indicate promising treatment efficacy [75], raising expectations for expanded indications in the future. Other common KRAS mutations in BTC include G12D, G12V, and G13D. A small-molecule inhibitor targeting KRAS G12D, MRTX1133, is currently in clinical trials for the treatment of solid tumors, including BTC (NCT05737706). Further development is eagerly awaited.

### TP53 mutations

Both iCCA and eCCA frequently exhibit TP53 mutations (Table 1) [44, 51, 72–74]. However, no actionable drug

is currently available, as therapies directly targeting TP53 mutations are still in development. TP53 is a tumor suppressor gene, and TP53 mutations are highly prevalent across various cancer types. The diversity of TP53 mutations (missense mutations, deletions, and insertions) and the structural complexity of the p53 protein have made targeted therapy development challenging. While direct therapies are limited, indirect approaches are being explored. One promising strategy is the restoration of mutant p53 function via the use of small molecules. For example, APR-246 (eprenetapopt) was designed to stabilize mutant p53 structurally and restore its normal function [76]. The combination of eprenetapopt with immune checkpoint inhibitors is currently being investigated in clinical trials, potentially including BTC patients (Table 2) [77]. As research progresses, novel therapeutic strategies tailored to TP53-mutant cancers are anticipated.

#### **ARID1A (AT-Rich Interactive Domain 1A) mutations**

Both iCCA and eCCA frequently exhibit ARID1A mutations (Table 1) [44, 51, 72]. ARID1A is a component of the SWI/SNF (Switch/Sucrose Nonfermentable) chromatin remodeling complex and functions as a tumor suppressor gene. Mutations in ARID1A lead to DNA repair defects and transcriptional dysregulation, contributing to tumor progression. While no specific targeted therapies for ARID1A mutations are currently available, several indirect approaches are under investigation. PARP (ADP-ribose) polymerase inhibitors and ATR (ataxia telangiectasia and Rad3-related) inhibitors, which target DNA repair deficiencies, may be effective [78]. Additionally, ARID1A mutations can increase the activity of EZH2 (Enhancer of Zeste Homolog 2), making EZH2 inhibitors (e.g., tazemetostat) promising therapeutic options [79]. These inhibitors are being evaluated in the treatment of BTC in clinical trials (Table 2, NCT05023655). Yoshino and colleagues demonstrated that ARID1A decreased histone H3K27 acetylation in cholangiocarcinoma cells, suggesting it as a potential therapeutic target [80]. Furthermore, tumors harboring ARID1A mutations may exhibit high microsatellite instability (MSI-H) or high tumor mutation burden (TMB), potentially rendering them responsive to immune checkpoint inhibitors such as pembrolizumab and nivolumab [81].

#### **CDKN2A/B (cyclin-dependent kinase inhibitor 2A/B) mutations**

Both iCCA and eCCA frequently exhibit CDKN2A/B mutations (Table 1) [44, 51, 72–74]; however, there is currently no direct targeted therapy for these mutations. CDKN2A is a tumor suppressor gene involved in cell cycle

regulation and encodes the proteins p16 (INK4A) and p14 (ARF), which modulate the RB and p53 pathways. Loss of p16/INK4A function due to CDKN2A mutations or deletions leads to increased CDK4/6 activity, uncontrolled cell cycle progression, and tumor growth. Consequently, CDK4/6 inhibitors (e.g., palbociclib, ribociclib, and abemaciclib) represent potential indirect therapeutic strategies. These inhibitors induce G1 cell cycle arrest and suppress tumor proliferation. CDK4/6 inhibitors for the treatment of BTC are currently being evaluated in clinical trials (Table 2, NCT02693535: TAPUR Group 4, Group 17, NCT04116541).

#### **EGFR (epithelial growth factor receptor) mutations**

EGFR mutations are frequently detected in iCCA (Table 1) [44, 82–85]. However, clinical trials of EGFR inhibitors (e.g., cetuximab, panitumumab, erlotinib) have not demonstrated sufficient efficacy [86–91], and no actionable drug is currently available. The efficacy of MRG003, an EGFR-targeting agent, for the treatment of EGFR-overexpressing BTC is being investigated in ongoing clinical trials (Table 2, NCT04838964). Future results are awaited with interest.

#### **PI3K (phosphoinositide 3-kinase) mutations**

Both iCCA and eCCA occasionally harbor PI3K mutations (Table 1) [44, 51]. Several targeted therapies for PI3K mutations are currently in development. PI3K mutations lead to dysregulation of the PI3K/AKT/mTOR signaling pathway, which promotes tumor growth and treatment resistance. This pathway is frequently altered in various cancers, and PI3K inhibitors, including the selective PI3K inhibitor alpelisib, which has been approved by the FDA for the treatment of PIK3CA-mutant HR-positive, HER2-negative breast cancer (based on the SOLAR-1 trial), have been developed [92]. Ongoing clinical trials are evaluating PI3K inhibitors in solid tumors, including BTC (Table 2, NCT06739395). Further advancements in treatment strategies are anticipated.

#### **BRAF mutation (V600E)**

BRAF mutations are observed across various cancer types, with the V600E mutation being particularly common in melanoma and colorectal cancer. In BTC, BRAF mutations are found in fewer than 5% of cases, with a higher prevalence in iCCA (Table 1) [52, 53]. The V600E mutation causes abnormal activation of the MAPK pathway independent of ligand stimulation, making it a therapeutic target for BRAF and MEK inhibitors. Clinical trials (ROAR trial) of dabrafenib (a BRAF inhibitor) and trametinib (a MEK inhibitor) in the treatment of BRAF V600E-mutated BTC have revealed promising results, and these drugs



are approved by the FDA for use in the treatment of BTC (Table 1) [31, 93]. The combination of vemurafenib and cobimetinib is currently being investigated in ongoing trials (Table 2).

### BRCA1/2 (breast cancer susceptibility gene) mutations

BRCA1/2 gene mutations are observed in 0–3% of BTC cases (Table 1) [94], making them relatively rare. BRCA genes are well known for their association with hereditary breast and ovarian cancers, and mutations in these genes lead to homologous recombination deficiency (HRD), resulting in the accumulation of DNA damage that drives carcinogenesis. In cancer cells harboring BRCA1/2 mutations, the inability to efficiently repair DNA interstrand crosslinks caused by platinum-based chemotherapy is expected to increase treatment efficacy. Since GC therapy is commonly used as the standard treatment for BTC [4, 7–9], platinum-based agents are often administered to all patients with advanced BTC regardless of BRCA1/2-mutation. Furthermore, the use of PARP inhibitors as second-line treatment is expected to prolong therapeutic effects, and clinical trials are currently ongoing [95].

### RET (rearranged during transfection) mutation

The RET proto-oncogene encodes a transmembrane receptor tyrosine kinase, and RET mutations drive oncogenic transformation in various cancers [96]. In RET fusion mutations, the RET gene fuses with a partner gene, often encoding a coiled-coil domain, leading to ligand-independent constitutive dimerization and subsequent kinase activation [97, 98]. The RET inhibitors selpercatinib and pralsetinib have demonstrated therapeutic efficacy in patients with RET-mutated solid tumors (Table 2) [99, 100]. Although RET mutations are relatively rare in BTC (0–6%, Table 1) [101, 102], these clinical trials included a small number of BTC patients, suggesting that these agents may also be effective in BTC patients with RET mutations.

### NTRK (neurotrophic tyrosine receptor kinase) mutations

Although NTRK fusions have been reported in only 0.2–0.7% of patients with BTC (Table 1) [103, 104], they are recognized as oncogenic driver genes in various tumor types. The NTRK gene family (NTRK1–3) encodes TRK proteins, which play crucial roles in normal neuronal development. However, when TRK fusion proteins are formed, they aberrantly activate tyrosine kinase activity, driving tumor progression. Two oral NTRK inhibitors, entrectinib and larotrectinib, are currently approved for use in patients with advanced NTRK fusion-positive solid tumors, including BTC. Both entrectinib and larotrectinib have demonstrated

clinical benefits in phase I/II clinical trials [33, 105]. These agents represent promising treatment options for BTC patients with NTRK fusions.

### SMAD4 mutation

There is currently no established specific targeted therapy for SMAD4 gene mutations. However, SMAD4 is a key molecule in the transforming growth factor- $\beta$  (TGF- $\beta$ ) signaling pathway, and abnormalities in this pathway are observed in many cancer types. As a result, therapies targeting pathways indirectly affected by SMAD4 mutations are being investigated. Among the clinical trials of FDA-approved drugs, a part of the MegaMOST trial is evaluating the use of regorafenib in solid tumors with biallelic inactivation of SMAD4 (Table 2). SMAD4 mutations have been reported in 11–25% of patients with eCCA (Table 1) [49], and it is anticipated that some of these trials will lead to the development of a new actionable drug for BTC.

## Discussion

This review summarizes the current frequency of genomic mutations in CCA and their potential for targeted therapy. Interestingly, IDH1 mutations rarely overlap with cases harboring FGFR fusion genes [106]. In support of this observation, cluster analysis of next-generation sequencing (NGS) results has demonstrated that cases can be categorized into four groups on the basis of the presence of IDH mutations, FGFR mutations, TP53 mutations, and CDKN2A mutations [107]. If these findings commonly hold true, the cumulative frequency of these genetic abnormalities suggests that a significant proportion of BTC patients could benefit from one of these targeted treatments. Numerous clinical trials of those targeted therapies are ongoing (Table 2), and if favorable results are obtained, the proportion of actionable genomic mutations is expected to significantly increase in the near future, increasing hope for improved outcomes.

Current mainstream genomic testing relies on tumor biopsy samples analyzed via NGS. However, obtaining tissue biopsies of BTC, especially for eCCA [25], can be challenging in terms of safety and ensuring adequate tissue quality for comprehensive molecular testing [45, 108], with approximately 70% of samples yielding sufficient tumor content for analysis. To complement testing for patients whose samples are insufficient for analysis, blood-derived circulating tumor DNA (ctDNA) analysis has been utilized. The NCCN and ESMO guidelines recommend considering tissue-based genomic testing first, and if it is challenging, ctDNA testing should be considered [2, 41]. ctDNA analysis offers certain advantages over tissue DNA sequencing, being

less invasive and increasingly available, with relatively high diagnostic accuracy for certain mutations (e.g., concordance rates: IDH1 mutation 87%; BRAFV600E 87%) [109]. However, lower concordance rates have been observed for certain mutations, such as FGFR2 fusions, which show an overall concordance rate of 18%, varying by fusion partner (FGFR2-BICC1 fusions 58%, FGFR2-other fusions 2.1%) [109]. For ctDNA, it is necessary to keep in mind the use of such tests with consideration for their limitations when conducting clinical practice, while this method also has the potential to enable real-time monitoring of genomic evolution. Further advancements in these methods are anticipated.

While promising, limitations of targeted therapy have also emerged. For example, the efficacy of gene-targeted treatments often diminishes after an average of 6–9 months (Table 1), possibly due to secondary mutations that confer resistance. ctDNA analysis revealed *de novo* point mutations in the FGFR2 gene, possibly conferring resistance to BGJ398 at the time of testing upon disease progression [110]. Goyal and colleagues reported the usefulness of ctDNA analysis for disease monitoring and the detection of acquired resistance during targeted therapy in a phase II study of the FGFR inhibitor infigratinib (BGJ398) [110]. Similar data were reported by Silverman and coworkers in the FIGHT-202 trial of pemigatinib in patients with FGFR-rearranged CCA by using either tissue or liquid biopsy testing [56]. Thus, in targeted therapy, not only for determining eligibility but also for predicting treatment efficacy, the use of blood samples to analyze ctDNA is expected to become increasingly valuable, highlighting the growing importance of this method.

Breakthroughs in targeted therapy have fundamentally different mechanisms of action compared with those of cytotoxic chemotherapies, potentially yielding superior efficacy. Moreover, the combination of targeted drugs with cytotoxic agents may produce synergistic, additive, or antagonistic effects, necessitating further exploration of optimal sequencing and safety. For example, the authors demonstrated a potential synergistic effect of FGFR inhibitors with gemcitabine [111]. Additionally, regarding FGFR2 inhibitors, the development of new, more potent selective FGFR inhibitors (e.g., RLY-4008, KIN-3248) is underway, which may circumvent drug resistance caused by point mutations, and there is growing anticipation for these advancements [112, 113]. Trials primarily focusing on targeted therapy alone are presented in Table 2; however, trials in which chemotherapy is combined with targeted therapy are also becoming more prominent. Future data are anticipated with great interest.

As targeted therapies demonstrate significant efficacy, the benefits and risks of their integration into treatment plans alongside surgical interventions must be carefully evaluated. Strategies such as initiating targeted therapy,

followed by minimal surgical intervention and adjuvant cytotoxic chemotherapy (or immune therapy), may emerge as viable approaches.

This review presents the current landscape of BTC genomic alterations and corresponding targeted therapies. In the future, targeted therapy is expected to become central to treatment planning. With the growing complexity of treatment options, leveraging artificial intelligence (AI) for treatment decision-making is likely to become standard practice. However, robust data and systematic clinical trials are needed to train AI systems effectively. The authors hope that this review contributes to these advancements and the establishment of optimal treatment frameworks.

**Acknowledgements** None.

**Authors' contributions** All the authors contributed to the study conception. DY performed the literature search and data analysis and wrote the first draft of the manuscript. SK, YD, and HE critically checked the manuscript. All the authors read and approved the final manuscript.

**Funding** Open Access funding provided by The University of Osaka. This research did not receive any specific grants from funding agencies in the public, commercial, or not-for-profit sectors.

## Declarations

**Competing interests** SK has received honoraria for lectures, presentations, speaker bureaus, and manuscripts from AstraZeneca, MSD, and Taiho Pharmaceutical. All the other authors declare that they have no conflicts of interest. The authors report no proprietary or commercial interests in any of the products mentioned or concepts discussed in this article.

**Ethics approval** This study did not require ethical approval because it was a review of published articles and did not directly involve human or animal subjects.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

1. Surgery JSOH-B-P (2021) General rules for Clinical and pathological studies on cancer of the biliary tract: the 7th edition. 7th edn., Tokyo

2. Network NCC (2024) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Biliary Tract Cancers Version 6.2024 [www.nccn.org/patients](http://www.nccn.org/patients). Accessed 2025/2/8 2025
3. Okawa Y, Iwasaki Y, Johnson TA et al (2023) Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer. *J Hepatol* 78(2):333–342
4. Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. *N Engl J Med* 362(14):1273–1281
5. Shroff RT, King G, Colby S et al (2025) SWOG S1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. *J Clin Oncol* 43(5):536–544
6. Endo I (2023) Recent progress in the treatment for unresectable biliary tract cancer. *Ann Gastroenterol Surg* 7(4):540–542
7. Oh DY, Ruth He A, Qin S et al (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. *NEJM Evid* 1(8):2200015
8. Kelley RK, Ueno M, Yoo C et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 401(10391):1853–1865
9. Ioka T, Kanai M, Kobayashi S et al (2023) Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MIT-SUBA). *J Hepatobiliary Pancreat Sci* 30(1):102–110
10. Higashi T, Kurokawa Y (2024) Incidence, mortality, survival, and treatment statistics of cancers in digestive organs-Japanese cancer statistics 2024. *Ann Gastroenterol Surg* 8(6):958–965
11. Okamura R, Kurzrock R, Mallory RJ et al (2021) Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. *Int J Cancer* 148(3):702–712
12. Carotenuto M, Sacco A, Forgiione L et al (2022) Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy. *Explor Target Antitumor Ther* 3(2):200–223
13. Kabbara KW, Cannon T, Winer A et al (2022) Molecular pathogenesis of cholangiocarcinoma: implications for disease classification and therapy. *Oncology (Williston Park)* 36(8):492–498
14. Gupta A, Kurzrock R, Adashek JJ (2023) Evolution of the targeted therapy landscape for cholangiocarcinoma: is cholangiocarcinoma the “NSCLC” of GI oncology? *Cancers* 15:5
15. Harding JJ, Khalil DN, Fabris L et al (2023) Rational development of combination therapies for biliary tract cancers. *J Hepatol* 78(1):217–228
16. LaPelusa M, Heumann T, Goff L et al (2023) Targeted therapies in advanced biliary tract cancers-a narrative review. *Chin Clin Oncol* 12(2):14
17. Moroney J, Trivella J, George B et al (2023) A paradigm shift in primary liver cancer therapy utilizing genomics, molecular biomarkers, and artificial intelligence. *Cancers* 15:10
18. Chotiprasidhi P, Sato-Espinoza AK, Wangenstein KJ (2024) Germline genetic associations for hepatobiliary cancers. *Cell Mol Gastroenterol Hepatol* 17(4):623–638
19. Gopal P, Robert ME, Zhang X (2024) Cholangiocarcinoma: pathologic and molecular classification in the era of precision medicine. *Arch Pathol Lab Med* 148(3):359–370
20. Grewal US, Gaddam SJ, Beg MS et al (2024) Targeted therapies in advanced biliary malignancies: a clinical review. *Expert Rev Anticancer Ther* 24(9):869–880
21. Khosla D, Misra S, Chu PL et al (2024) Cholangiocarcinoma: recent advances in molecular pathobiology and therapeutic approaches. *Cancers* 16:4
22. Mie T, Sasaki T, Okamoto T et al (2024) Current status of targeted therapy for biliary tract cancer in the era of precision medicine. *Cancers* 16:5
23. Speckart J, Rasmusen V, Talib Z et al (2024) Emerging therapies in management of cholangiocarcinoma. *Cancers* 16:3
24. Yoo C, Hyung J, Chan SL (2024) Recent advances in systemic therapy for advanced intrahepatic cholangiocarcinoma. *Liver Cancer* 13(2):119–135
25. Ettrich TJ, Schwerdel D, Dolnik A et al (2019) Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information. *Sci Rep* 9(1):13261
26. Zhu AX, Macarulla T, Javle MM et al (2021) Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. *JAMA Oncol* 7(11):1669–1677
27. Abou-Alfa GK, Macarulla T, Javle MM et al (2020) Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Oncol* 21(6):796–807
28. Abou-Alfa GK, Sahai V, Hollebecque A et al (2020) Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. *Lancet Oncol* 21(5):671–684
29. Goyal L, Meric-Bernstam F, Hollebecque A et al (2023) Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. *N Engl J Med* 388(3):228–239
30. Harding JJ, Fan J, Oh D-Y et al (2023) Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. *Lancet Oncol* 24(7):772–782
31. Subbiah V, Lassen U, Élez E et al (2020) Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. *Lancet Oncol* 21(9):1234–1243
32. Doebele RC, Drilon A, Paz-Ares L et al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. *Lancet Oncol* 21(2):271–282
33. Hong DS, DuBois SG, Kummar S et al (2020) Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. *Lancet Oncol* 21(4):531–540
34. Matsumura N, Mandai M (2024) PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of sacituzumab govitecan for breast cancer, fruquintinib for colorectal cancer, amivantamab for lung cancer, repotrectinib for lung cancer, tasurgratinib for biliary tract cancer, enfortumab vedotin plus pembrolizumab for urothelial cancer, and dabrafenib plus trametinib for glioma in Japan. *Int J Clin Oncol* 29(12):1775–1776
35. Matsumura N, Mandai M (2024) PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of pembrolizumab for gastric and biliary tract cancer and encorafenib and binimetinib for thyroid cancer in Japan. *Int J Clin Oncol* 29(8):1053–1054
36. Bridgewater J, Galle PR, Khan SA et al (2014) Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. *J Hepatol* 60(6):1268–1289
37. Service NCCICI (2025) Cancer Type Statistics: Gallbladder & Bile Duct. [https://ganjoho.jp/reg\\_stat/statistics/stat/cancer/9\\_gallbladder.html](https://ganjoho.jp/reg_stat/statistics/stat/cancer/9_gallbladder.html).
38. Rimassa L, Brandi G, Niger M et al (2023) Diagnosis and treatment of cholangiocarcinoma in Italy: a delphi consensus statement. *Crit Rev Oncol Hematol* 192:104146
39. Loong HH, Shimizu T, Prawira A et al (2023) Recommendations for the use of next-generation sequencing in patients with



- metastatic cancer in the Asia-Pacific region: a report from the APODDC working group. *ESMO Open* 8(4):101586
40. Zhang D, Dorman K, Westphalen CB et al (2024) Unresectable biliary tract cancer: current and future systemic therapy. *Eur J Cancer* 203:114046
  41. Vogel A, Bridgewater J, Edeline J et al (2023) Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up☆. *Ann Oncol* 34(2):127–140
  42. Mateo J, Chakravarty D, Dienstmann R et al (2018) A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT). *Ann Oncol* 29(9):1895–1902
  43. Mosele F, Remon J, Mateo J et al (2020) Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. *Ann Oncol* 31(11):1491–1505
  44. Montal R, Sia D, Montironi C et al (2020) Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. *J Hepatol* 73(2):315–327
  45. Stenzinger A, Vogel A, Lehmann U et al (2024) Molecular profiling in cholangiocarcinoma: a practical guide to next-generation sequencing. *Cancer Treat Rev* 122:102649
  46. Inada H, Miyamoto H, Shinriki S et al (2024) Clinical utility of a comprehensive genomic profiling test for patient with advanced biliary tract cancer. *Int J Clin Oncol* 29(12):1908–1915
  47. Borger DR, Tanabe KK, Fan KC et al (2012) Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. *Oncologist* 17(1):72–79
  48. Kipp BR, Voss JS, Kerr SE et al (2012) Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. *Hum Pathol* 43(10):1552–1558
  49. Churi CR, Shroff R, Wang Y et al (2014) Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. *PLoS ONE* 9(12):e115383
  50. Mondesir J, Willekens C, Touat M et al (2016) IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. *J Blood Med* 7:171–180
  51. Lowery MA, Ptashkin R, Jordan E et al (2018) Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. *Clin Cancer Res* 24(17):4154–4161
  52. Brindley PJ, Bachini M, Ilyas SI et al (2021) Cholangiocarcinoma. *Nat Rev Dis Primers* 7(1):65
  53. Takeda T, Sasaki T, Fukuda K et al (2021) Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients. *Int J Clin Oncol* 26(3):543–551
  54. Zhuravleva E, O'Rourke CJ, Andersen JB (2022) Mutational signatures and processes in hepatobiliary cancers. *Nat Rev Gastroenterol Hepatol* 19(6):367–382
  55. Fuente MIDL, Colman H, Rosenthal M et al (2020) A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas: safety and efficacy as single agent and in combination with azacitidine. *J Clin Oncol* 38(15):2505–2505
  56. Silverman IM, Hollebecqre A, Friboulet L et al (2021) Clinico-genomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib. *Cancer Discov* 11(2):326–339
  57. Arai Y, Totoki Y, Hosoda F et al (2014) Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. *Hepatology* 59(4):1427–1434
  58. Graham RP, Barr Fritcher EG, Pestova E et al (2014) Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. *Hum Pathol* 45(8):1630–1638
  59. Maruki Y, Morizane C, Arai Y et al (2021) Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study). *J Gastroenterol* 56(3):250–260
  60. Javle M, Lowery M, Shroff RT et al (2018) Phase II study of BGJ398 in patients With FGFR-altered advanced cholangiocarcinoma. *J Clin Oncol* 36(3):276–282
  61. Mazzaferro V, El-Rayes BF, Droz Dit Busset M et al (2019) Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. *Br J Cancer* 120(2):165–171
  62. Bekaii-Saab TS, Valle JW, Van Cutsem E et al (2020) FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. *Future Oncol* 16(30):2385–2399
  63. Makawita S, Ghassan KA-A, Roychowdhury S et al (2020) Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial. *Future Oncol* 16(30):2375–2384
  64. Galdy S, Lamarca A, McNamara MG et al (2017) HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? *Cancer Metastasis Rev* 36(1):141–157
  65. Nam A-R, Kim J-W, Cha Y et al (2016) Therapeutic implication of HER2 in advanced biliary tract cancer. *Oncotarget* 7:36
  66. Bouattour M, Valle JW, Vogel A et al (2023) Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer. *J Clin Oncol* 41(4):531–531
  67. Kim H, Kim R, Kim HR et al (2022) HER2 aberrations as a novel marker in advanced biliary tract cancer. *Front Oncol* 12:9
  68. Ohba A, Morizane C, Kawamoto Y et al (2024) Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm phase II trial. *J Clin Oncol* 42(27):3207–3217
  69. Cannon TL, Rothe M, Mangat PK et al (2024) Pertuzumab plus trastuzumab in patients with biliary tract cancer with <i>ERBB2/3</i> alterations: results from the targeted agent and profiling utilization registry study. *J Clin Oncol* 42(27):3228–3237
  70. Nakamura Y, Mizuno N, Sunakawa Y et al (2023) Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-positive metastatic biliary tract cancer (SGNTUC-019): a phase II basket study. *J Clin Oncol* 41(36):5569–5578
  71. Jhaveri KL, Wang XV, Makker V et al (2019) Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. *Ann Oncol* 30(11):1821–1830
  72. Javle M, Bekaii-Saab T, Jain A et al (2016) Biliary cancer: Utility of next-generation sequencing for clinical management. *Cancer* 122(24):3838–3847
  73. Lee H, Wang K, Johnson A et al (2016) Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. *J Clin Pathol* 69(5):403–408
  74. Xue L, Guo C, Zhang K et al (2019) Comprehensive molecular profiling of extrahepatic cholangiocarcinoma in Chinese population and potential targets for clinical practice. *Hepatob Surg Nutr* 8(6):615–622
  75. Ou S-HI, Jänne PA, Leal TA et al (2022) First-in-human phase I/IB dose-finding study of adagrasib (MRTX849) in patients with advanced <i>KRAS</i> <sup><i>G12C</i></sup> solid tumors (KRYSTAL-1). *J Clin Oncol* 40(23):2530–2538

76. Lehmann S, Bykov VJN, Ali D et al (2012) Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. *J Clin Oncol* 30(29):3633–3639
77. Park H, Shapiro GI, Gao X et al (2022) Phase Ib study of eprentapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors. *ESMO Open* 7(5):100573
78. Shen J, Peng Y, Wei L et al (2015) ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. *Cancer Discov* 5(7):752–767
79. Keller PJ, Adams EJ, Wu R et al (2024) Comprehensive target engagement by the EZH2 inhibitor tulmimetostat allows for targeting of ARID1A mutant cancers. *Cancer Res* 84(15):2501–2517
80. Yoshino J, Akiyama Y, Shimada S et al (2020) Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma. *Carcinogenesis* 41(6):734–742
81. Mullen J, Kato S, Sicklick JK et al (2021) Targeting ARID1A mutations in cancer. *Cancer Treat Rev* 100:102287
82. Nakazawa K, Dobashi Y, Suzuki S et al (2005) Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. *J Pathol* 206(3):356–365
83. Yoshikawa D, Ojima H, Iwasaki M et al (2008) Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. *Br J Cancer* 98(2):418–425
84. Gwak GY, Yoon JH, Shin CM et al (2005) Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. *J Cancer Res Clin Oncol* 131(10):649–652
85. Leone F, Cavalloni G, Pignochino Y et al (2006) Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. *Clin Cancer Res* 12(6):1680–1685
86. Gruenberger B, Schueller J, Heubrandtner U et al (2010) Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. *Lancet Oncol* 11(12):1142–1148
87. Malka D, Cervera P, Foulon S et al (2014) Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. *Lancet Oncol* 15(8):819–828
88. Sohal DP, Mykulowycz K, Uehara T et al (2013) A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma. *Ann Oncol* 24(12):3061–3065
89. Leone F, Marino D, Cereda S et al (2016) Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: a randomized phase 2 trial (Vecti-BIL study). *Cancer* 122(4):574–581
90. Philip PA, Mahoney MR, Allmer C et al (2006) Phase II study of erlotinib in patients with advanced biliary cancer. *J Clin Oncol* 24(19):3069–3074
91. Lee J, Park SH, Chang HM et al (2012) Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol* 13(2):181–188
92. André F, Ciruelos E, Rubovszky G et al (2019) Apolisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. *N Engl J Med* 380(20):1929–1940
93. Subbiah V, Kreitman RJ, Wainberg ZA et al (2023) Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. *Nat Med* 29(5):1103–1112
94. Spizzo G, Puccini A, Xiu J et al (2020) Molecular profile of BRCA-mutated biliary tract cancers. *ESMO Open* 5(3):e000682
95. Kim Y, Ok B, Park I et al (2023) Randomized phase 2 study of maintenance olaparib vs olaparib plus durvalumab for DNA damage repair (DDR) gene mutated unresectable or metastatic biliary tract cancer (BTC) with durable response to first-line platinum-based chemotherapy: OPTIMUM trial. *J Clin Oncol* 41(16):4180
96. Subbiah V, Cote GJ (2020) Advances in targeting RET-dependent cancers. *Cancer Discov* 10(4):498–505
97. Mulligan LM, Kwok JB, Healey CS et al (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. *Nature* 363(6428):458–460
98. Grieco M, Santoro M, Berlingieri MT et al (1990) PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. *Cell* 60(4):557–563
99. Subbiah V, Wolf J, Konda B et al (2022) Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. *Lancet Oncol* 23(10):1261–1273
100. Subbiah V, Cassier PA, Siena S et al (2022) Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial. *Nat Med* 28(8):1640–1645
101. Adashek JJ, Desai AP, Andreev-Drakhlin AY et al (2021) Hallmarks of RET and co-occurring genomic alterations in RET-aberrant cancers. *Mol Cancer Ther* 20(10):1769–1776
102. Kato S, Subbiah V, Marchlik E et al (2017) RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients. *Clin Cancer Res* 23(8):1988–1997
103. Solomon JP, Linkov I, Rosado A et al (2020) NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. *Mod Pathol* 33(1):38–46
104. Demols A, Rocq L, Perez-Casanova L et al (2023) A Two-step diagnostic approach for NTRK gene fusion detection in biliary tract and pancreatic adenocarcinomas. *Oncologist* 28(7):e520–e525
105. Demetri GD, Paz-Ares L, Farago AF et al (2018) Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumors: pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001. *Ann Oncol* 29:175
106. Farshidfar F, Zheng S, Gingras MC et al (2017) Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. *Cell Rep* 18(11):2780–2794
107. Mody K, Jain P, El-Refai SM et al (2022) Clinical, genomic, and transcriptomic data profiling of biliary tract cancer reveals subtype-specific immune signatures. *JCO Precis Oncol* 6:e2100510
108. Lamarca A, Kapacee Z, Breeze M et al (2020) Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers. *J Clin Med* 9(9):2854
109. Berchuck JE, Facchinetti F, DiToro DF et al (2022) The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer. *Ann Oncol* 33(12):1269–1283
110. Goyal L, Saha SK, Liu LY et al (2017) Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. *Cancer Discov* 7(3):252–263
111. Ito Y, Yamada D, Kobayashi S et al (2024) The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma. *Cancer Lett* 595:216997
112. Subbiah V, Sahai V, Maglic D et al (2023) RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations. *Cancer Discov* 13(9):2012–2031
113. Balasooriya ER, Wu Q, Ellis H et al (2024) The irreversible FGFR inhibitor KIN-3248 overcomes FGFR2 kinase domain mutations. *Clin Cancer Res* 30(10):2181–2192

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.